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  DESCRIPTION of CASE
    A 
40-year-old woman presented to a tertiary-care facility 
on the 11th of October 2004, having been referred 
from a private-health clinic for continued treatment 
of thyrotoxicosis. The referring doctor had started her on 
carbimazole, 60 mg daily 11 months earlier. She discontinued 
treatment after three months for ﬁ  nancial reasons. She was 
referred to the state tertiary facility because the fees there are 
subsidized.
    At presentation on the 11th of October 2004, she had no 
overt symptoms of hyperthyroidism. Physical examination 
revealed a well-looking woman with a soft, smooth, nontender 
moderately sized diffuse thyromegaly with no bruit. Her 
palms were warm and moist with palmar erythema. There 
was a mild tremor of the outstretched ﬁ  ngers. There were 
no obvious eye signs of thyrotoxicosis or Graves disease. The 
patient’s heart rate was 87 beats per minute and regular, with 
a blood pressure of 134/70 mm Hg. There were no features 
of cardiac decompensation or proximal myopathy. 
    Her thyroid function test results and therapeutic 
interventions are as shown in Table 1. Thyroid 
antimicrosomal and antithyroglobulin antibodies were 
positive with titres of 1:400 and 1:40, respectively (Table 1). 
    What Was the Diagnosis and Treatment?
    A diagnosis of thyrotoxicosis due to Graves disease was 
made on the basis of smooth diffuse thyromegaly and 
positive markers of thyroid autoimmunity. As the patient 
had not received adequate medical therapy, carbimazole 
was reintroduced at 40 mg daily. She was counselled that 
adequate medical treatment would require daily compliance 
with the prescribed medication for a period of 12–18 months. 
She was hopeful about complying with this, as the medical 
fees were affordable. 
    However, she re-presented three weeks later with 
progressively deepening jaundice, pruritus, and passage 
of clay-coloured stools. There was no previous history of 
jaundice, blood transfusions, intravenous drug abuse, 
anaesthesia, recent history of travel, or animal exposure. Her 
son, however, had recently become jaundiced. She did not 
consume alcohol, but did receive a two-monthly injectable 
contraceptive progestagen (Nuristerate) for the four years 
preceding presentation. 
    She was markedly jaundiced on examination. There were no 
peripheral stigmata of chronic liver disease. There was no right 
hypochondrial tenderness, hepatomegaly, features of hepatic 
encephalopathy, or cardiac decompensation.  
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    What Is the Differential Diagnosis of Jaundice 
in a Patient with Thyrotoxicosis?
    Several causes of jaundice should be entertained in this 
patient. The aetiology may be multifactorial. The differential 
diagnosis of this patient’s jaundice can be divided into 
(1) thyrotoxicosis per se and conditions associated with 
autoimmune thyroid disease, including thionamide therapy, 
hepatic congestion from thyrotoxic heart failure, hepatic 
necrosis from systemic embolisation caused by atrial 
ﬁ  brillation, autoimmune hepatitis, and primary biliary 
cirrhosis, which may be associated with Graves disease, and 
(2) causes of jaundice unrelated to thyrotoxicosis, such 
as viral hepatitis, sepsis, cholangitis, alcohol abuse, and 
medication such as hormonal contraceptives, acetaminophen, 
isoniazid, rifampicin, and herbal remedies.
    The pattern of liver function test abnormalities may 
suggest an aetiology for the jaundice. While hepatocellular 
damage is classically characterised by elevated serum 
transaminase levels with minimal increase in serum alkaline 
phosphatase (hepatocellular pattern), the converse is the 
case with obstructive causes of jaundice (obstructive pattern). 
However, many conditions that cause jaundice give a mixed 
hepatocellular/obstructive pattern. 
    The recent onset of jaundice in her son suggested the 
possibility of viral hepatitis. She was subsequently managed as 
an in-patient from 5 November 2004–29 November 2004. 
  Which  Investigations Were  Performed?
    Haemoglobin and white blood cell count were normal at 12.1 
g/dl and 10,400/cm3, respectively. Serum urea, electrolytes, 
and creatinine were normal. 
    Her serology was negative for hepatitis A anti-IgM antibody, 
hepatitis B surface antigen, hepatitis B core anti-IgM, 
hepatitis B surface anti-IgM, hepatitis B antigen, and hepatitis 
C virus anti-IgM. She was, however, positive for Hepatitis C 
anti-IgG, indicating prior exposure to hepatitis C. Her serial 
liver function test results are shown in Table 2.
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    Her antinuclear antibody was positive at a titre of 1:160. 
Anti-liver-kidney microsomal and antimitochondrial antibodies 
were negative. The abdominal ultrasound demonstrated 
a normal sized liver with no focal lesions. The bile ducts, 
pancreas, kidney, and spleen were all reported as normal. 
    In view of the negative hepatitis serology and the possibility 
of autoimmune hepatitis, a liver biopsy was undertaken once 
contraindications to the procedure (such as derangements in 
coagulation proﬁ  le) had been excluded. One may, however, 
argue that a conservative approach could have been taken. In 
other words, rather than performing a liver biopsy, we could 
have opted to observe for the expected improvement in liver 
function test abnormalities and jaundice on discontinuation 
of the carbimazole therapy. The decision to perform a liver 
biopsy in this patient was based on the need to exclude 
autoimmune hepatitis, given the fact that she already had 
elevated liver enzymes before starting carbimazole therapy 
and given the raised serum titres of antinuclear antibodies. 
Autoimmune hepatitis may have been an additional cause of 
the patient’s jaundice that would have needed treatment in its 
own right. 
    Liver biopsy is not without risks, which include 
haemoperitoneum, biliary peritonitis, sepsis, and 
pneumothorax. Precautionary measures are needed, such 
as knowing the patient’s coagulation status, having stand-
by cross-matched blood, and strict asepsis and periodic 
monitoring of haemodynamic status after the procedure. 
Ultrasound guidance may be necessary in the following 
conditions: obesity, ascites, reduced liver span, and focal 
hepatic lesions. Our patient had a blind liver biopsy after 
initial ultrasound scan had shown a normal liver size with no 
focal lesions. The biopsy tract was, however, plugged with 
gelatin foam to prevent bleeding. The histological ﬁ  nding 
was of striking cholestasis and lobular inﬂ  ammation, which 
was predominantly lymphocytic. There were few neutrophils 
and eosinophils with mild portal inﬂ  ammation. There 
were, however, no plasma cells as would be expected in 
autoimmune hepatitis.
    What Was the Cause of Jaundice in This Patient?
    Although her son proved to have active hepatitis A infection, 
this was excluded in our patient by negative serology. The 
probable cause of jaundice would appear to be carbimazole 
since it developed three weeks after it was recommenced. The 
presence of eosinophils on liver histology was suggestive of an 
allergic aetiology for the hepatobiliary damage. Carbimazole-
induced hepatic damage is thought to be allergic in aetiology 
and is typically predominantly cholestatic, as depicted in this 
patient (Table 2). 
    Thionamide-induced hepatobiliary damage usually occurs 
within three months of therapy and may occur despite 
previous uneventful exposure to the drug. A contributory 
effect from hormonal contraceptive use cannot be excluded. 
The liver enzyme tests done by the referring facility as of 
25 September 2003 (i.e., even before she was started on 
carbimazole therapy) were already mildly deranged (Table 2).
  Table 1.   Thyroid Function Test Results and Dates Performed with Therapy Received   
25
September 
2003
4
July
2004
11
October 
2004
5
November 
2004
21
November 
2004
3
December 
2004
1
January 
2005
9
May 
2005
Therapy
received
Carbimazole Yes Yes Yes
Cholestyramine Yes Yes
Radioactive I131 Yes
Thyroxine Yes
Test results Free thyroxine (pmol/l) 
(10.3–21.9)
60.6 77 74.5 28.9 49.8 17.9 6.3
Free tri-iodothyronine 
FT3 (pmol/l) (3.1–6.6)
12.6 20.1
Thyroid stimulating 
hormone (miu/l) 
(0.35–4.5)
< 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 55.06
  DOI:  10.1371/journal.pmed.0030012.t001 
  Table 2.   Serial Liver Function Test Results   
Test 25 September 2003 16 November 2004 21 November 2004 3 December 2004 29 December 2004
Total bilirubin (µmol/l) (0–21) 10 145 257 143 36
Conjugated bilirubin (µmol/l) (0–6) 2 101 187 105 25
Alkaline phosphatase (u/l) (40–120) 54 216 257 149 124
Gamma glutaryl (u/l) (0–35)   NA 94 65 66 93
Lactate dehydrogenase (u/l) (210–430) 372 456 444   NA 296
Aspartate transferase (u/l) (5–40) 41 47 37 49 49
Alanine transferase (u/l) (5–40) 46 73 42 71 62
Total serum protein (g/l) (60–85) 75 80 78 68 75
Serum albumin (g/l) (35–52) 41 43 41 37 44
  NA,  not  available
  DOI:  10.1371/journal.pmed.0030012.t002 
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    How Did the Patient’s Investigations Affect 
Her Management?
    Carbimazole therapy was immediately discontinued, and the 
patient was advised about alternative nonhormonal methods 
of contraception. She was started on cholestyramine, 12 
g daily in divided doses, and atenolol (a beta-blocker), 50 
mg daily. A nonselective beta-blocker such as propranolol 
is preferable when choosing a beta-blocker for treating 
thyrotoxicosis. High doses should be used as the thyrotoxic 
state potentiates the metabolic clearance of beta-blockers. 
Propranolol, in addition to nonselective beta-blockade, 
has the beneﬁ  t of inhibiting the peripheral conversion 
of thyroxine to the more potent triiodothyronine. While 
cholestyramine interferes with the enterohepatic circulation 
of thyroid hormones, atenolol attenuates the peripheral 
effects of circulating thyroid hormones. Radioactive iodine 
therapy was subsequently administered once pregnancy had 
been excluded. 
    How Did the Patient Respond?
    The jaundice resolved over a period of three months from 
presentation. Hypothyroidism was diagnosed ﬁ  ve months 
after radioactive iodine treatment, and thyroxine, 50 mcg 
daily, was started. 
    DISCUSSION
    Thyroid dysfunction may perturb liver function, and the liver 
modulates thyroid hormone metabolism. A variety of systemic 
diseases and drugs may affect both organs [1,2].
    Thyrotoxicosis and Hepatobiliary Injury
    Abnormal liver biochemical test results have been reported 
in hyperthyroid patients before and after antithyroid 
therapy. Gurlek et al. [3] showed that 60.5% of 43 patients 
with hyperthyroidism had at least one liver abnormality at 
diagnosis. Hepatic damage occurring from thyrotoxicosis 
per se has been ascribed to ischaemic injury resulting from a 
relative decrease in blood ﬂ  ow despite increased metabolic 
activity of the liver [1]. But bear in mind that raised alkaline 
phosphatase may not be of liver origin but rather from bone, 
indicating an osteoblastic response to thyroid hormone-
induced bone resorption.
    The nature of hepatic injury caused by thionamides is 
dependent on the speciﬁ  c drug. While carbimazole and its 
active metabolite methimazole typically cause cholestasis, 
propylthiouracil (PTU) is notable for causing hepatocellular 
injury [4–7]. Thionamide-induced liver damage is an 
idiosyncratic reaction that can develop at any time, but 
usually occurs within the ﬁ  rst three months of treatment. 
It occurs in about 1% of patients, with a predisposition for 
women younger than 30 years of age [1]. The mechanism 
of injury is thought to be based on an allergic host response 
[1,4,8]. 
    Our patient had a predominantly cholestatic hepatitis, 
which is consistent with cases of carbimazole- and 
methimazole-induced hepatic damage reported in the 
literature [9–11]. Thionamide therapy may be an additional 
insult to the liver. Khoo Ai-Leng et al. [12] reported a case 
of fatal hepatic failure in a patient on carbimazole and 
bupropion, while Enghofer et al. [13] reported fulminant 
hepatitis A infection in a hyperthyroid patient treated with 
carbimazole. Therefore, we suggest that it might be prudent 
to exclude additional risk factors for liver injury in patients 
presenting with thionamide-associated cholestasis.
    Therapeutic Options in Our Patient
    Substitution of one thionamide for the other has been 
suggested as a treatment approach for thionamide-induced 
hepatotoxicity. Indeed, Waseem et al. [14] reported a 
successful outcome when a patient with PTU-induced 
hepatitis was treated with a combination of methimazole 
and lithium. We, however, did not consider this option 
in our patient, as PTU is not readily available in South 
Africa and it is potentially hepatotoxic. After initial therapy 
with cholestyramine and atenolol, the patient received 
radioactive iodine therapy. This was not associated with 
additional morbidity. Her outcome was in keeping with the 
review of a meta-analysis of reports of patients with PTU-
associated hepatotoxicity, which showed favourable outcomes 
despite most patients receiving radioactive iodine before 
hepatic function test abnormalities had resolved [8]. While 
thyroidectomy is a preferred modality of management in 
many centres, we rarely use it. Hypothyroidism was diagnosed 
ﬁ  ve months after radioactive iodine therapy, and thyroxine 
therapy was promptly started. Hypothyroidism may, however, 
develop many years after radioactive iodine therapy. This 
underscores the need for life-long follow-up after radioactive 
iodine therapy, as hypothyroidism does cause considerable 
morbidity and can trigger or exacerbate thyroid eye disease.   
  Key Learning Points 
    •  Jaundice as a complication of thionamide treatment of 
hyperthyroidism is rare. 
    •  This complication cannot be predicted by deranged liver 
enzymes at presentation, but typically occurs within three 
months of therapy. 
    •  It can be fatal, particularly when there are additional 
hepatotoxic factors. 
    •  The subsequent management of hyperthyroidism should 
ideally be with proven alternative methods without a 
hepatotoxic potential. 
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